Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

Infection research stands at the forefront of global health initiatives, particularly considering emerging pathogens and antimicrobial resistance. The quest for effective interventions necessitates ...

Global epidemiological trend of Klebsiella pneumoniae ST340: emergence of subclade KL15 co-producing K pneumoniae ...

Pneumonia in the elderly can quickly become serious and deadly. On World Pneumonia Day, know the symptoms of this infection ...

Every year there are millions of cases of pneumonia all over the world, and it is a severe health issue globally. Pneumonia ...